# Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

> **NCT00028366** · NA · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 56 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Fosamprenavir
- **DRUG:** Lopinavir/Ritonavir
- **DRUG:** Ritonavir
- **DRUG:** Tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT00028366
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 56 (—)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028366, "Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00028366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*